Peptide Encyclopedia / Thymogen
EncyclopediaThymogen is a synthetic dipeptide, glutamyl-tryptophan, from the Khavinson bioregulator family, reported to influence T-lymphocyte differentiation and immune regulation. Its mechanism stays poorly characterized in Western literature, and the name is sometimes confused with the distinct peptide thymosin alpha-1. It is not FDA-approved in the US, where it holds research-chemical status. Below you'll find reported dosing, safety, and legal status. Educational only, not medical advice.
| Category | Immune |
| Regulatory status | Not FDA-approved in the US (research chemical status). |
A synthetic dipeptide (glutamyl-tryptophan, a Khavinson bioregulator) reported to act as an immunomodulator influencing T-lymphocyte differentiation and immune regulation. Note: 'Thymogen alpha-1' is sometimes conflated with thymosin alpha-1, a distinct thymic peptide; the dipeptide form is the classic Thymogen. Mechanism is not well characterized in peer-reviewed Western literature.
Not established; limited human pharmacokinetic data.
Not FDA-approved in the US (research chemical status). Registered as an immunomodulatory drug in the Russian Federation; no US marketing authorization.
Reported as well tolerated in Russian clinical use; independent Western safety data are lacking. Sterility/purity risks apply to unregulated product. Caution: do not assume equivalence to thymosin alpha-1.
Human use/studies primarily from Russia; no independent Western randomized controlled trials. Evidence quality is limited.
PepWise is an informational and educational tracking tool, not medical advice and not a medical device. Thymogen may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.
